reference/9858796

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/9858796

Outgoing Links

Predicate	Object
contentType	Clinical Trial\|Journal Article\|Randomized Controlled Trial\|Research Support, Non-U.S. Gov't
endingPage	268
issn	0002-8703
issueIdentifier	2
pageRange	263-268
publicationName	American Heart Journal
startingPage	263
bibliographicCitation	Bhatt DL, Topol EJ; Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance Executive Committee. Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Am Heart J. 2004 Aug;148(2):263–8. doi: 10.1016/j.ahj.2004.03.028. PMID: 15308995.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f9f41fdd437a209df70627756bf87c1b http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f3a9862513491ef51bfbe923afceaaa1
date	200408
identifier	https://pubmed.ncbi.nlm.nih.gov/15308995 https://doi.org/10.1016/j.ahj.2004.03.028
isPartOf	http://rdf.ncbi.nlm.nih.gov/pubchem/journal/398 https://portal.issn.org/resource/ISSN/0002-8703
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://www.crossref.org/
title	Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: Rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial
discusses	http://id.nlm.nih.gov/mesh/M0155432 http://id.nlm.nih.gov/mesh/M0017012 http://id.nlm.nih.gov/mesh/M0021526 http://id.nlm.nih.gov/mesh/M0001864
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D013988Q000627 http://id.nlm.nih.gov/mesh/D010975Q000627 http://id.nlm.nih.gov/mesh/D001241Q000627 http://id.nlm.nih.gov/mesh/D013927Q000188 http://id.nlm.nih.gov/mesh/D013988Q000031 http://id.nlm.nih.gov/mesh/D001161Q000188
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D002318Q000517 http://id.nlm.nih.gov/mesh/D001161Q000517 http://id.nlm.nih.gov/mesh/D002318Q000401 http://id.nlm.nih.gov/mesh/D000077144 http://id.nlm.nih.gov/mesh/D013927Q000150 http://id.nlm.nih.gov/mesh/D012107 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D008875 http://id.nlm.nih.gov/mesh/D013927Q000517 http://id.nlm.nih.gov/mesh/D011322 http://id.nlm.nih.gov/mesh/D001161Q000150 http://id.nlm.nih.gov/mesh/D004359 http://id.nlm.nih.gov/mesh/D012307 http://id.nlm.nih.gov/mesh/D016032
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID60606 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8564 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8198 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9412 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2244 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11015 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7969 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID10602 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11310

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127968075 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128918298 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127563695

Total number of triples: 55.